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Hamster to rat renal xenotransplantation was per-
formed with recipient nephrectomies. Recipients 
were treated beginning on day 0 with continuous FK 
506 monotherapy, a 7-day or open-ended monothera-
peutic course of cyclophosphamide (CP),* and the two 
drug regimens combined. CP alone (10 mglkglday) pre-
vented a xenospecific antibody response and tripled 
median survival of the kidney (defined as recipient 
death) from 6 (control) to 18.5 days whereas FK 506 
alone had no effect. The drugs in combination were no 
better than CP alone (15 days) unless the 5-day course 
of CP was given at a higher dose (15 mg/kg) and started 
3 days preoperatively (79 days). In further experi-
ments, adjuvant measures were added to the mini-
mally effective FK 506l7-day CP regimen which gave a 
median survival of only 15 days. In the most successful 
modification, intraoperative antibody depletion by 
the temporary transplantation of third party hamster 
liver or en bloc kidneys increased median survival 
from 15 to 34 and 48 days, respectively. An intraoper-
ative i.v. dose administration of the anticomplement 
drug K76 instead of antibody depletion increased sur-
vival to 26 days. Although the events of kidney rejec-
tion were similar to those of heart xenografts and par-
tially forestalled by the antibody inhibiting CP 
treatment, or by antibody depletion, survival for> 100 
days was accomplished in only 5 of 86 treated animals. 
The poorer survival previously reported with cardiac 
xenotransplantation is largely explained by the life 
support requirement of the kidneys. Renal failure was 
responsible for almost all deaths before 60 days, and 
subnormal renal failure was a pervasive adverse 
factor thereafter, frequently caused by pyelonephritis 
which is suspected to have had an immunologic 
etiology. 
Hamster to rat heart and liver transplantations have been 
widely used to study xenograft rejection (1-9), but there has 
been no recorded experience with the kidney except for our 
preliminary technical description of a model (10). We report 
here the effects on the hamster renal xenograft of a variety of 
familiar or new therapeutic protocols, most of which already 
have been evaluated previously with other organs. These 
included FK 506, cyclophosphamide (CP), the anticomple-
ment drug K76, and antibody depletion by prior or contem-
poraneous transplantation of donor species kidneys or livers. 
Long survival ofthe kidney xenograft proved more difficult to 
1 Address correspondence to: Dr. T.E. Starzl, Department of Sur· 
gery, Pittsburgh Transplant Institute, University of Pittsburgh, PA 
15213. 
achieve than previously observed with either the heart or 
liver. 
MATERIALS AND METHODS 
Animals 
Inbred male Lewis rats (LEW, RTll Harlan Sprague Dawley Inc., 
Indianapolis, IN) weighing 200-300 g were recipients, and Golden 
Syrian hamsters (Charles River Laboratory, Wilmington, MAl 
weighing 100-150 g were donors. 
Surgical Procedure and Animal Care 
Orthotopic kidney transplantation. Methoxyflurane inhalation 
anesthesia was given. The hamster left kidney was mobilized and 
removed, leaving the left renal artery in continuity with a segment of 
the aorta, and the left renal vein with a cuff of the inferior vena cava 
(10). The full ureter was retained in continuity with a piece of 
bladder. After donor heparinization (200 U), the xenograft was ex-
cised and infused via the aorta with 1-3 ml cold lactated Ringer's 
solution. Using a 10-0 Novafil suture, the end of the graft aorta was 
anastomosed to the side of the recipient infrarenal aorta and the 
graft left renal vein cuff to the side of the adjacent inferior vena cava. 
The donor bladder patch was sewn to the recipient bladder, followed 
by recipient nephrectomies. Graft rejection was defined as the time 
of death. Animals that died within 7 days with obvious surgical 
complications (15%) were eliminated from analysis. The most com-
mon causes of exclusion were leak or hemorrhage at the bladder 
anastomosis. 
Antibody depletion. The "expendable" organs were from third 
party hamster donors. The portal vein of the donor liver or the aorta 
in continuity with en bloc kidneys were arterialized by cuff anasto-
mosis to the carotid artery, with venous drainage into the recipient 
jugular vein. After ligating the unused open vessels of the grafts, 
these "antibody trap" organs were perfused for 1.5-2 hr, beginning 
before and continuing throughout transplantation of the definitive 
kidneys, and then disconnected. 
Animal care and sampling. Postoperative intramuscular cefa-
mandole nafate was given for 3 days. Body weight and activity were 
recorded daily. Blood (0.5 ml) was taken from the tail vein 1 day after 
grafting and weekly thereafter postoperatively; serum creatinine 
and anti-hamster lymphocytotoxic antibodies were measured in the 
samples. 
Immunosuppressive Agents 
FK 506 (Fujisawa Pharmaceutical Co. Ltd., Osaka, Japan) was 
dissolved in normal saline and given intramuscularly in doses of 1 or 
2 mglkg/day. CP, prepared daily in distilled water, was given by 
gastric instillation in doses of 7.5-15 mg/kg/day. The anticomple-
ment agent, K76 monocarboxylic acid (K76) (11,12) (Otsuka Phar-
maceutical Co., Ltd., Tokushima, Japan), was dissolved in normal 
saline, and 200 mg/kg was injected intravenously 30 min before graft 
* Abbreviation: CP, cyclophosphamide. revascularization. 
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Experimental Design 
The course of unmodified animals (group 1) was compared with 
that under FK 506 or CP alone (groups 2-4 and 10), and in combi-
nation (groups 5 and 6). The group 5 regimen of FK 506 and CP was 
selected for the addition of further therapeutic variables: antibody 
depletion with third party liver and kidney in groups 11 and 12, 
respectively, an increased dose of CP which was advanced into the 
preoperative period in group 14, and a prevascularization intrave-
nous dose of the complement inhibiting drug, K76 in group 13. The 
treatment schedules for experimental and control groups are sum-
marized in Table 1. 
Antibody Studies 
Of serum. Lymphocytotoxic antibodies were measured with a 
complement-fixing assay, using donor hamster lymphocytes as tar-
gets (3, 13). The recipient sera were heat-inactivated (56°C for 30 
min) and serially diluted with RPMI 1640. One microliter of various 
dilutions of serum samples and 1 ,...1 of hamster lymphocyte suspen-
sions (4X106/ml) were incubated for 30 min at room temperature. 
After addition of 5 ,...1 baby rabbit complement (1:5 dilution, Cedar-
lane Laboratories Limited, Hornby, Ontario), the mixture was rein-
cubated for 60 min at room temperature. After trypan blue staining 
and fIXation, cell lysis was scored, and the lymphocytotoxic antibody 
titer was defined as the most dilute serum sample with greater than 
50% cell lysis. Samples were run in duplicate. 
Of tissue. Direct immunofluorescence studies were performed in 
separate animals. Untreated animals were killed 1 hr (n=3), 1 day 
(n=3), or 3 days (n=2) after transplantation. Animals which were 
antibody-depleted with kidney perfusion and treated with FK 506 
and CP (as in group 12) were killed 1 hr (n=2), 1 day (n=3), or 6 days 
(n=3) after transplantation. K76-treated animals (treated as in 
group 13) were also killed 1 hr after grafting (n=3). The xenografts 
were embedded in optimal cold temperature compound at -76°C, cut 
into 4-,...m sections, and incubated with FITC-conjugated goat anti-
rat IgG or IgM (Accurate Chemical & Scientific Corp., Westbury, NY) 
or anti-rat complement C3 (Organon Teknika Corporation, Cappel 
Research Products, Durham, NC). The location and intensity of Ig 
and complement deposits were examined blindly without knowledge 
of treatment protocols or the time of sampling. 
Statistical Analysis 
Mann-Whitney U test was used to compare statistical differences 
in animal survival between groups. A P value less than 0.05 was 
considered significant. 
RESULTS 
Animal Survival and Graft Function 
Animal survival. The 6-day survival of untreated controls 
was not increased with FK 506 monotherapy (group 2, Table 
1) but rose to 8 days and 18.5 days with daily 7.5 and 10 
mglkg CP monotherapy, respectively (groups 3 and 4). The 
CP benefit was not augmented with the addition of FK 506 
(groups 5 and 6). The combination of 1 mglkg/day FK 506 and 
a 7-day postoperative course of 10 mglkg CP (group 5) which 
gave a median survival of 15 days was chosen as baseline for 
the evaluation of added therapeutic variables that were in-
effectual when used alone (groups 7-9). 
The 15-day median survival of group 5 was prolonged to 34 
days (vs. group 5, P=0.06, NS) by perioperative antibody 
depletion with hamster livers (group 1~I Table 1), to 48 days 
(P<0.05) when paired kidneys were used for the depletion 
(group 12), and to 26 days with a single prevascularization 
dose of Lv. K76 (P=O.I, NS) (group 13). However, the longest 
survival of 79 days was in animals given continuous FK 506 
plus the higher daily dose of 15 mglkg CP for 5 days divided 
equally between the pre- and postoperative periods (group 
14); animals given the same regimen of CP alone died within 
10 days (group 10). 
Only 5 animals of the 96 in the study lived for more than 
100 days (Table 1}-218 in group 12 and 3/9 in group 14. 
Graft function and body weight. The animals of groups 
1-6 were ill almost from the time of xenotransplantation-
losing weight and with rapid increases in serum creatinine 
with a few exceptions that were multiple only in group 4 (Fig. 
TABLE 1. LEW rat recipient survival after hamster kidney transplantation: effect of FK 506, CP, K76, and organ perfusion 
Treatment p 
Group Organ Survival (days) Median FK50SB CP Duration perfusion n (days) 
(mg/kglday) (mglkglday) (days) (va. group 1) (VB. group 5) 
1 10 5, 5, 5, 5, 6, 6, 6, 6, 6, 6 6.0 
2 2.0 11 RIRIRI~SI~SI~SI 7,7 6.0 NSc 
3 7.5 O-+death 7 6,7,8,8,8,9,20 8.0 <0.005 
4 10.0 O-+death 6 6,11,13,24,28,30 18.5 <0.005 
5 1.0 10.0 l~ 7 5,5,6,15,18,27,30 15.0 <0.005 
6 OKMuS~1KM 10.0 l~ 6 8,10,11,12,33,57 11.5 <0.005 <0.05 
7 Liver 3 5,5,6 5.0 NS 
8 Kidney 3 5,6,6 6.0 NS 
9b 5 7,7,7,7,7 7.0 <0.005 
10 15.0 -P~1 6 9,9,9,9,10,10 9.0 <0.005 
11 1.0 10.0 l~ Liver 9 12,13,14,22,34,37,38, 34.0 <0.001 NS 
79,86 
12 1.0 10.0 l~ Kidney 8 9,12,26,33,63,92,130, 48.0 <0.001 <0.05 
133 
13b 1.0 10.0 l~ 6 9,19,25,27,43,46 26.0 <0.005 NS 
14 1.0 15.0 -P~1 9 7, 11, 13, 16, 79, 79, 102, 79.0 <0.001 NS 
118,126 
a FK 506 was intramuscularly injected at indicated doses for 30 days and continued at 0.5 mg/kg/day every other day thereafter. 
b K76 (200 mg/kg i.v.) was given before transplantation as a bolus injection. 
eNS, not significant (Mann-Whitney U test). 
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1). The rats in group 4 which had open-ended treatment with 
CP appeared to die of drug toxicity. 
In contrast, the majority of animals in groups 11, 12, and 
14 reversed the early postoperative weight loss and had 
periods of stability for days or weeks before secondary dete-
rioration that most commonly was associated with sharp 
rises in serum creatinine (Fig. 1). Eleven rats which survived 
for more than 60 days, including the five that went beyond 
100 days, had final serum creatinine values that were at or 
below 3 mg%, but none was normal. 
Antibody Studies 
Of serum. Anti-hamster lymphocytotoxic antibodies 
promptly 'rose in the untreated animals of group 1 and in 
those treated only with FK 506, reaching 28 to 213 by the time 
of death (Fig. 2). CP in doses of 10 mg/kg/day prevented this 
increase in all animals whether or not the CP was open-
ended or limited to 6 days. The CP benefit was independent 
of FK 506 and was not obviously enhanced by antibody de-
pletion. In rats that survived for more than 1 month, titers 
drifted up late, but never to high levels (Fig. 2). 
Of tissue. The most remarkable change seen by direct 
immunofluorescence in the untreated kidney xenograft 1 hr 
after reperfusion was intense deposition of IgM» IgG in the 
main vessels (Fig. 3). These increased with time. By 1-3 days 
the glomerular capillary loops and interstitium became IgM 
positive (Fig. 4); however, IgG deposits are not prominent. 
When preformed antibodies were depleted either by kid-
ney or liver perfusion, or pretreatment with CP, IgM deposits 
in main vessels 1 hr after grafting were significantly de-
creased (Fig. 5). 
Histopathology 
Mild spotty hyalinization was observed in the untreated 
kidney grafts obtained 1 hr after grafting. Hyalinoid degen-
eration increased with time and involved whole vessel walls 
in 24 hr. Three to 5 days after transplantation, the vessels 
showed classical features of humoral rejection. Microthrombi 
were present in small arteries, arterioles, and glomerular 
capillaries, resulting in extensive tubular necrosis. There 
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were diffuse interstitial hemorrhages and perivascular and 
glomerular neutrophil infiltration, but no mononuclear infil-
trates (Fig. 6). 
In long-surviving animals, mild to moderate cellular infil-
trates were seen in a few sections. Vasculitis, including inti-
mal proliferation and obliterative arteriopathy, was occasion-
ally observed, suggesting that antibody-mediated graft 
damage was not completely abolished. Evidence of pyelone-
phritis caused by urinary tract obstruction was a common 
finding in long-surviving animals. 
Complement Studies 
One hour after transplantation untreated hamster kidney 
showed diffuse rat C3 deposits along the main vessels. Pre-
operative bolus K76 injection (200 mg/kg) completely pre-
vented C3 deposition (Fig. 7). 
DISCUSSION 
The events and mechanisms of hamster heart and liver 
rejection in rat recipients are well-known. The existence of 
low level hamster specific xenoantibodies in normal rats has 
been demonstrated with in vitro cytotoxic assays using ham-
ster lymphocytes or endothelial cells as targets (2-9, 14, 15) 
and with an indirect immunofluorescence assay showing xe-
nospecific Ig binding to tissues (3, 6, 14). Despite these omi-
nous findings, hyperacute rejection of the heart and liver 
does not occur in this species combination. However, rapid B 
cell activation and xenospecific antibody production causes 
pure humoral rejection of the heart in 3 days (3-9, 14). The 
liver with its well-known resistance to antibody rejection (16) 
is destroyed in 7 days by a combination of humoral and 
cellular rejection (3, 4, 14). 
The exclusively humoral kidney xenograft rejection ob-
served in the present study, occurring over a 3-day period 
rather than hyperacutely, was comparable histopathologi-
cally to that of the hamster heart. Within less than 1 hr, 
deposition of rat IgM» IgG on the endothelium of the main 
intraparenchymal renal vessels was striking, but less than in 
the hyperacutely rejecting pig kidney transplanted to the dog 
(17), Rhesus monkey (18, 19), or baboon (20). As with ham-
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FIGURE 2. Changes of anti-hamster 
lymphocytotoxic antibody titers after 
hamster kidney transplantation. 
Groups are identical to those in Figure 
1 and in the text. 10 10 10 
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FIGURE 3. Hamster kidney graft 1 hr after grafting in untreated 
Lewis rat recipient. Intense IgM deposition on the vessels (A) and 
weak deposits of IgG (E). (Direct immunofluorescence, FITC-conju-
gated goat anti rat IgG or IgM.) 
ster hearts, the humoral rejection was not altered by treatment 
with the T cell-directed FK 506, but was markedly attenuated 
by suppressing B cell antibody production with CPo The efficacy 
ofCP in the kidney experiments, as in previous reports with the 
20 40 60 80 100 
FIGURE 4. Untreated hamster kidney graft 5 days after transplan-
tation in the rat. Intense IgM deposits are seen in the glomerular 
loops and the interstitium. (Direct immunofluorescence, FITC-con-
jugated goat anti rat IgM.) 
other organs, was attributable to its prevention of the astro-
nomical increases in lymphocyte toxicity titers that otherwise 
occur. The hwnoral rejection also was mitigated by depleting 
the antibodies with "forerunner" donor organs as has been 
described in hypersensitized allograft recipients (21), and with 
various species combinations to protect kidney, heart, or liver 
xenograft;s (17, 22-24). AB we reported long ago in a direct 
comparison of the liver, kidney, and spleen, none of these or-
gans was strikingly superior for antibody depletion (17). We 
obtained better results in the present study using en bloc 
kidneys than we did with the liver. 
The critical role of complement in hwnoral rejection has been 
well-demonstrated with transplantation across widely diverse 
species barriers as well as with transplantation to hyperimmu-
nized allograft recipients. In most such experiments, the anti-
body-initiated classical pathway of complement activation has 
been incriminated (25). However, hyperacute allograft or xe-
nograft. rejection also can be caused by activation of the alter-
native complement pathway not involving antibody collabora-
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FIGURE 5. Hamster kidney graft 1 hr after grafting in recipient 
pretreated with kidney perfusion (right) or high dose CP (left). In-
tense rat IgM deposits were significantly reduced, compared with 
those of untreated recipient in Figure 3. (Direct immunofluores-
cence, FITC-conjugated goat anti rat IgM.) 
tion (26,27). Anticomplement agents which interfere with both 
pathways at different levels include cobra venom factor (28) and 
recombinant soluble complement receptor type I (29, 30). Pro-
longed heart graft survival in the concordant hamster-rat model 
has been accomplished by combining cobra venom factor and 
CsA (5). These agents mitigate hyperacute rejection in pig-to-
dog (28), pig-to-primate (18-20), and guinea pig-to-rat (20, 29, 
30) xenografts, but the effect is temporary in the discordant 
species. 
K76, which inhibits C5 convertase and thus disables both 
pathways proximal to the membrane attack complex, has 
been used in the guinea pig-to-rat heart model with minimal 
effect when given intraperitoneally (31), but with a much 
greater prolongation of survival when the drug was admin-
istered intravenously at the same dose (32). Intravenous K76 
in the present study also appeared to prolong hamster-to-rat 
kidney xenograft survival, but with the small number of 
experiments (n=6) and the short survival of one of the K76-
treated animals, the therapeutic effect was short of statisti-
cal significance (P=O.l) when compared with FK 506-CP 
alone (median 15 vs. 26 days). 
Although the events of kidney xenograft rejection and the 
degree of their amelioration with antibody control strategies 
were generally comparable to those reported earlier with the 
heart, animal survival was inferior. Rather than connoting 
an immunologic disadvantage of the kidney, this can be ex-
plained by the life support function of the kidney xenograft 
compared with the physiologically superfluous role of the 
heterotopic heart. Deaths before 60 days almost invariably 
were preceded by unremitting weight loss, and in most ani-
mals, except those of group 4 treated with presumably toxic 
open-ended CP, this was associated with striking increases 
in serum creatinine despite suppression of the antibody re-
sponse which outlasted CP treatment in more successful 
cases. After 60 days, maintenance or gain in weight was 
associated with better, but still abnormally elevated, creati-
nine concentrations, consistent with a pervasive mortality 
factor of renal failure. These animals produced a large vol-
.me of unconcentrated urine, which sometimes reached 
three to six times more volume than that of normal rat. This 
.. . 
r • , 
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FIGURE 6. (A) Untreated hamster kidney graft 5 days after grafting. 
Platelet and neutrophilic sludging can be seen in this interlobular 
artery (arrow) and the glomerulus immediately above the center of 
the photomicrograph (H&E, lOO X). (B) A high magnification of the 
glomerulus shows capillary loops thrombosis, neutrophilic sludging 
and collapse of the loops, all of which are indicative of humoral 
rejection (H&E, 300x). 
impaired renal function might be explained by the chronic 
immunological damages. However, there might be a func-
tional disparity between the rat and hamster kidney. This 
possibility is currently under investigation. 
Histopathologically, vascular damage and signs of pyelo-
nephritis reminiscent of the vasculopathic biliary tract le-
sions previously reported in liver xenografts were the most 
common abnormalities in the long surviving kidneys. As with 
the biliary tree, obstruction of the graft urinary tract for 
technical reasons often could not be ruled out. Several meth-
ods for urinary tract reconstruction have been described to 
decrease the incidence of pyelonephri tis and stone formation 
in the tiny rat drainage conduits (33). The ureter-ureter and 
ureter-bladder anastomoses, which have been used for the 
rat kidney transplantation with more than 85% success, al-
ways resulted in anastomosis breakdown in the hamster-to-
rat transplantation, because of the short and thin hamster 
ureter. We chose the technique of bladder-to-bladder recon-
struction; however, the poor vascularization of the distal 
graft ureter and bladder could defeat the purpose intended. 
The alternative possibility that obstruction of xenograft 
collecting systems had an immunologic etiology is supported 
I 
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FIGURE 7. Intense rat complement C3 deposits were seen in the 
main vessels of untreated hamster kidney graft (left: 1 hr after 
grafting). In K76-treated animal (200 mgikg i.v.), C3 deposition was 
dramatically reduced (right). (Direct immunofluorescence, FITC-
conjugated goat anti rat C3 .) 
by experience in liver transplantation in which biliary ob-
struction was dramatically reduced by using better immuno-
suppressive protocols (3). 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
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